카테고리 :IGF-1 단백질
Interestingly, PT-141 was pulled from clinical trials before it reached approval for use in women
suffering from HSDD. This is despite signs that the drug increased the number of satisfying sexual
events per month and decreased female sexual distress scores in a statistically significant manner
without any substantial side effects . Many experts who treat female sexual dysfunction (FSD) were
dismayed to find the peptide was not being advanced despite positive results. They point to a lack of
established endpoints for trials of FSD and socio-cultural biases against women’s sexual health as the
primary roadblocks that are inhibiting approval of what they see as much-needed therapies . They
hope that greater attention will be given to the topic and that the FDA will establish more concrete
guidelines for evaluating therapies like PT-141 that can offer benefit. These experts also expressed
dismay that the pharmacological treatments were not tested in conjunction with other established
means of treating sexual dysfunction as they believe that the combination may prove synergistic and
that peptides like PT-141 may be useful for overcoming initial barriers and jump-starting psychological
treatment modalities.
In 2017, partly in response to the outcry against the cessation of earlier trials, Phase II Reconnect
trials were launched using subcutaneous injections of PT-141 for FSD. The newest version of PT-141,
called Rekynda, may soon be available for use in the United States. It would be legal to use PT-141
off-label, at that point, to treat both male and female sexual dysfunction . These new trials have relied
on the kind of modified endpoints that experts in FSD have touted as beneficial to seeing these kinds
of treatments approved.PT-141 및 출혈2009 년에 PT-141은 약간 수정되어 출혈 충격에 대한 잠재적 치료로 조사되었습니다. PT-141은 MC-1R 및 MC-4R 둘 다에 결합하기 때문에, 허혈성 (출혈) 충격의 설정에서 허혈을 감소시키고 부적절한 혈액 공급으로 조직을 보호합니다. 약물은 정맥으로 투여 될 때 실질적인 부작용을 일으키지 않습니다. IIB 단계 시험에서 마지막이었습니다. PT-141의 수정 된 버전은 PL-6983이라고합니다.
PT-141 및 감염The MC-1R has been found, in a rat model of a specific fungal infection, to possess important anti fungal and anti-inflammatory properties . This is of particular importance because current anti fungals are limited in terms of their mechanism of action and all produce serious and treatment-limiting side effects in certain patients. Having an alternative to use in the treatment of fungal infections could
reduce morbidity and mortality substantially, especially in patients with immune compromise.
PT-141 및 암MC-1R 수용체는 DNA 복구 경로의 중요한 자극이므로 암 치료 및 예방에 관심이 있습니다 [1O]. 연구에 따르면 MC-1R의 변이체를 가진 사람들은 기저 세포 및 편평 세포 암종 모두에 대한 위험이 증가하고 있습니다.연구 방향Right now, PT-141 has received widespread and intense attention as a treatment forsexual dysfunction. There is, however, a great deal of potential research outside of sexualdysfunction and hemorrhage that PT-141 could be applied to. For instance, MC-4R iswell-known to be defective or missing in certain cases of obesity and may account for asmuch as 6% of all cases of early-onset obesity. PT-141 offers a unique means ofexploring this particular cause of obesity and potentially illustrating a pathway forintervention. MC-1R plays roles in both pain and inflammation as well as kidneypathology and the spread of infection. There is a plethora of available research that PT.141 could help to shed light on.
PT-141 exhibits minimal side effects, low oral and excellent subcutaneous bioavailabilityin mice. Per kg dosage in mice does not scale to humans. PT-141 for sale at PeptideSciences is limited to educational and scientific research only, not for humanconsumption. Only buy PT-141 if you are a licensed researcher.
기사 저자위의 문헌은 Dr. Logan, M.D. Dr. Loganhold의 Dr. Western Reserve University School of Medicine에서 박사 학위를 받았다.
과학 저널 저자Dr. Sheryl A. Kingsberg is the chief of behavioral medicine at University Hospitals CaseMedical Center and professor in Reproductive Biology and Psychiatry at Case WesternReserve University. Her areas of clinical specialization include sexual medicine, femalesexual disorders, cognitive behavioral psychotherapy, menopause, pregnancy andpostpartum mood disorders, psychological aspects of infertility, and psychological andsexual aspects of cancer. Dr. Kingsberg’s primary research interests are in treatments forfemale sexual disorders and the psychological aspects of infertility and menopause. Sheled a randomized, placebo-controlled dose-finding trial for PT-141. She has numerouspublications in many national and international journals, sits on the editorial board ofMenopause and has authored numerous chapters on topics including perimenopauseand sexuality, oocyte donation, infertility and aging, the treatment of psychogenic erectiledysfunction and sexuality after cancer. Dr. Kingsberg received her PhD from theUniversity of South Florida in Tampa and completed her fellowship in sexual medicine atUniversity Hospitals Case Medical Center. She is an active member in a number ofnational and international organizations including the American Psychological Associationand the American Society for Reproductive Medicine. She currently sits on the Board ofTrustees of The North American Menopause Society, and serves as the current treasurerof the Society for Assisted Reproductive Technologies. Dr. Kingsberg s a past president ofThe International Society for the Study of Women’s Sexual Health.
Dr. Sheryl A. Kingsberg is being referenced as one of the leading scientists involved inthe research and development of PT-141. In no way is this doctor/scientist endorsing oradvocating the purchase, sale, or use of this product for any reason. There is no affiliationor relationship, implied or otherwise, between PEPTIDE GURUS and this doctor. Thepurpose of citing the doctor is to acknowledge, recognize, and credit the exhaustiveresearch and development efforts conducted by the scientists studying this peptide. Dr.Kingsberg is listed in [12] under the referenced citations.참조 인용1.M. Sandrock, A. Schulz, C.Merkwitz,T. Schöneberg, K. Spanel-Borowski, and A.Ricken, “Reduction in corpora lutea number in obese melanocortin-4-receptor-deficient mice,”Reprod. Biol. Endocrinol.RBE, vol.7, p.24, Mar. 2009.
2.R.C.Rosen, L.E.Diamond, D.C. Earle, A. M. Shadiack, and P. B. Molinoff.*Evaluation of the safety, pharmacokinetics and pharmacodynamic effects ofsubcutaneously administered PT-141, a melanocortin receptor agonist, in healthymale subjects and in patients with an inadequate response to Viagra,” Int. J. lmpotRes.,vol.16,no.2,pp.135-142,Apr.2004.[PubMed]
3.H.Wessells, V. J. Hruby, J. Hackett, G. Han, P. Balse-Srinivasan, and T. W.Vanderah,“Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection viabrain and spinal melanocortin receptors,” Neuroscience, vol. 118, no. 3, pp. 755-762.2003.[PubMed]
4.A.-S. Rössler, J. G. Pfaus, H. K. Kia, J. Bernabé, L.Alexandre, and F. Giuliano,“The melanocortin agonist, melanotan ll, enhances proceptive sexual behaviors inthe female rat,”Pharmacol. Biochem.Behav., vol.85, no.3, pp.514-521, NOV.2006.[PubMed]
5.M.R.Safarinejad and S.Y. Hosseini, “Salvage of sildenafil failures withbremelanotide: a randomized, double-blind, placebo controlled study,” J. Urol., vol.179,no.3,pp.1066-1071,Mar.2008.[PubMed]
6.A. H. Clayton et al., “Bremelanotide for female sexual dysfunctions inpremenopausal women: a randomized, placebo-controlled dose-finding trial,Womens Health Lond.Engl., vol.12,no.3, pp.325-337,2016.[PubMed]
7.M.K. Miller, J.R. Smith, J. J. Norman, and A. H. Clayton,“Expert opinion onexisting and developing drugs to treat female sexual dysfunction,” Expert Opin.Emerg.Drugs, vol.23,no.3,pp.223-230,2018.[PubMed]
8.“AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive LicensingAgreement for North American Rights to RekyndaTM (bremelanotide), a PotentialTreatment for a Common Female Sexual Disorder -AMAG Pharmaceuticals.[MarketWatchl]
9.H. Ji et al.. “The Synthetic Melanocortin (CKPV)2 Exerts Anti-Fungal and Anti.Inflammatory Effects against Candida albicans Vaginitis via Inducing MacrophageM2 Polarization,”PLoS ONE, vol.8, no.2,Feb.2013.[PLOS ONE]
10.V. Maresca, E. Flori, and M. Picardo, “Skin phototype: a new perspective,” PigmentCell Melanoma Res., vol.28,no.4,pp.378-389,Jul.2015.[PubMed]
11.L. Feller, R. a. G. Khammissa, B. Kramer, M. Altini, and J. Lemmer, “Basal cellcarcinoma, squamous cell carcinoma and melanoma of the head and face,” HeadFace Med., vol.12,p.11,Feb.2016.[PubMed]
12.Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexualdysfunctions in premenopausal women: a randomized, placebo-controlled dose.finding trial. Womens Health (Lond), 2016:12(3):325-337. doi:10.2217/whe-2016-0018
13.T.R. McMillan, M. A. M. Forster, L.l. Short, A. P. Rudecki, D.L. Cline, and S. L.Gray, “Melanotan ll, a melanocortin agonist, partially rescues the impairedthermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficientmice,Exp.Physiol.,vol.106,no.2,pp.427-437,Feb.2021, doi:10.1113/EP088838.”
14.C.Spana, R. Jordan, and S. Fischkoff, “Effect of bremelanotide on body weight ofobese women: Data from two phase 1 randomized controlled trials,Diabetes ObesMetab., vol.24,no.6,pp.1084-1093, Jun.2022, doi: 10.1111/dom.14672
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.Peptidegurus는 미국에서 만든 연구 펩티드의 주요 공급 업체로 경쟁력있는 가격으로 최고 품질의 제품을 제공합니다. 우수성 및 고객 서비스에 중점을 두어 글로벌 배송으로 안전하고 편리한 주문 프로세스를 보장합니다.
© Copyright Peptide Gurus 2024. 모든 권리 보유.개인정보처리방침 이 사이트의 모든 제품은 연구, 개발용으로만 제공됩니다. 제품은 어떤 종류의 인간 섭취도 허용되지 않습니다. 이 웹사이트에 실린 진술들은 미국 식품의약국(FDA)이나 캐나다 보건부의 평가를 받은 적이 없습니다. 이 회사의 진술서와 제품은 어떠한 질병의 진단, 치료, 치유 또는 예방을 목적으로 하지 않습니다. 펩타이드구루스는 화학 공급업체입니다. 펩타이드구러스는 연방 식품, 의약품 및 화장품법 503A조에 정의된 조제 약국이나 화학 조제 시설이 아닙니다. 펩타이드 사이언스는 연방 식품, 의약품 및 화장품법 503B조에 따라 정의된 아웃소싱 시설이 아닙니다.
연락하다
